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Cardiogenic shock complicates approximately 5-10% of all myocardial infarction 
and remains the most common cause of death amongst these patients. Over the 
past few decades, the mortality associated with cardiogenic shock has improved 
with the introduction of early revascularization although there is limited data in 
patients with triple-vessel disease and left main stem disease. In more recent 
years, there have been a number of advances in the mechanical circulatory 
support devices that can help improve the haemodynamics of patients in 
cardiogenic shock. Despite these advances, together with progress in the use of 
inotropes and vasopressors, cardiogenic shock remains associated with a high 
morbidity and mortality. This review will outline the management of cardiogenic 
shock complicating acute myocardial infarction with major focus on 
revascularization techniques and the use of mechanical circulatory support 
devices.  
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Introduction 
Cardiogenic shock is a clinical condition of inadequate end-organ perfusion due 
to cardiac dysfunction (Table 1). It most commonly occurs in the setting of acute 
myocardial infarction with left ventricular failure (~80% cases)1,2, but can also be 
caused by right ventricular infarction or late mechanical complications, such as 
acute mitral regurgitation or ventricular rupture (septal or free wall). Non-infarct 
related cardiogenic shock is comparatively rare, and may result from 
decompensated valvular heart disease and arrhythmias, to name a few 
mechanisms.  
The pathophysiology of cardiogenic shock is complex and we will touch on this 
briefly here; myocardial ischaemia induces marked depression of myocardial 
contractility, which sets into motion a downward spiral of reduced cardiac output 
and hypotension, which in turn drives further myocardial ischaemia. This severe 
cardiac dysfunction causes tissue hypoperfusion and may eventually result in 
death if the vicious cycle is not adequately interrupted by timely treatment 
measures. In addition to the physiological impairment of myocardial function, 
cardiogenic shock also induces deleterious systemic responses including 
pathological vasodilation (after compensatory vasoconstriction), systemic 
inflammation with capillary leakage and impairment of the microcirculation1,3.  
This review will look at the optimal management of patients with cardiogenic 
shock complicating acute myocardial infarction with particular focus on 
revascularisation therapy and the use of mechanical circulatory support devices.  
 
Incidence and prognosis of cardiogenic shock 
Cardiogenic shock complicates 5-15% of cases of acute myocardial infarction, 
and despite advances in acute care there remains the same incidence (~60,000 
– 70,000 patients per year in Europe) 2,4.  
Historically, myocardial infarction complicated by cardiogenic shock was 
associated with a mortality rate of 80-90%5. However, with advances in coronary 
reperfusion techniques over the past few decades, especially with the 
introduction of primary percutaneous percutaneous coronary intervention, the 
mortality rate has improved to below 50%4,6-12. The trend toward better outcomes 
may also be due to greatly awareness of the need for timely treatment, 
improvements in the medical care of haemodynamically unstable patients as well 
as the use of mechanical support devices, though this has not yet been clearly 
demonstrated.  
Despite this high mortality, it is important to note that patients with cardiogenic 
shock that survive to discharge have a long-term outcome similar to patients 
without cardiogenic shock, with a good functional outcome at one-year13,14. This 





(a) Myocardial Reperfusion 
There is evidence that the high mortality associated with cardiogenic shock has 
improved over time7,9,11,15,16. This benefit is thought to be due to increased use of 
coronary revascularisation strategies, which by restoring flow to the ischaemic 
myocardium, can limit infarct size, as well as interrupt the downward spiral that 
characterises cardiogenic shock7,9,15.  
As such, the cornerstone of management in cardiogenic shock complicating 
acute myocardial infarction is prompt revascularization as highlighted in the 
‘Should we emergently revascularize Occluded Coronaries for Cardiogenic 
Shock’ (SHOCK) trial17. Patients with cardiogenic shock were randomly assigned 
to initial medical stabilization or early revascularization (PCI or CABG within 6 
hours of randomization and 18 hours of onset of shock). The primary endpoint 
(all cause mortality at 30 days) did not differ between the initial medical 
stabilization and early revascularization group, however there was a significant 
decrease in mortality at one and six years in patients assigned to early 
revascularization14,17,18. The number needed to save one life at one year by early 
revascularization in comparison to initial medical stabilization is less than eight, 
and this benefit remained with long-term follow up (Figure 1).   
The same trial also demonstrated the importance of timely revascularization, with 
an increasing long-term mortality as time to revascularization increased from 0  to 
8 hours. However, the overall benefit of revascularization in cardiogenic shock 
may extend past the traditional 12 hour window post-myocardial infarction to 
potentially as long as 54 hours after myocardial infarction and 18 hours after 
shock onset18,19.  
In current European Society of Cardiology guidelines, early revascularization by 
either PCI or CABG for cardiogenic shock is recommended20 but despite general 
increased tends to perform early revascularization, real-world rates remain 
relatively low (50-70%)2,14,21.   
 
- Anti-platelet & anti-thrombotic medication 
The clinical syndrome of cardiogenic shock impairs enteral absorption which may 
result in suboptimal bioavailability of oral agents22. In addition, patients in 
cardiogenic shock often require mechanical ventilation and this poses problems 
with oral medication (overcome with nasogastric tube insertion and delivery of 
crushed tablets) which further complicates matters23. In general, patients with 
cardiogenic shock should be loaded with aspirin as routinely recommended in 
acute coronary syndromes – however, administration of oral P2Y12 inhibitors 
should be deferred until coronary angiography as CABG may be immediately 
required20. Although not yet licensed, cangrelor (a fast-acting and rapidly 
reversable intravenous P2Y12 inhibitor) may prove to useful in these situations 
where oral anti-platelet administration may be delayed or unreliable24.  
Given the above problems with oral administration of anti-platelet agents, 
glycoprotein IIb/IIIa-inhibitors may be beneficial in cardiogenic shock. 
Observational data suggests a potential mortality benefit with their use in 
cardiogenic shock, but one randomised trial (of only 80 patients) did not 
demonstrate any benefit of routine abciximab use compared to use at the 
discretion of the interventionalist25. As such, current guidelines recommend use 
of GP IIb/IIIa-inhibitors as bailout therapy for thrombotic complications during PCI 
and whilst limiting the recommendation for their routine use during PCI for 
STEMI20,26.  
During PCI, adjunctive anticoagulation with unfractionated heparin, low-molecular 
weight heparin or direct thrombin inhibitors should be co-administered with 
antiplatelet therapy. With a lack of specific randomised trials in cardiogenic 
shock, the same recommendations apply as for other types of acute coronary 
syndrome20.  
 
- What is the ideal method of early revascularization?  
Coronary reperfusion can be achieved with thrombolytic therapy (in patients with 
STEMI), PCI, or emergency CABG. There is a paucity of randomized data 
assessing the efficacy of thrombolytic therapy compared to either placebo or PCI 
in patients who have cardiogenic shock at presentation. The available studies 
have demonstrated some benefit of thrombolytic therapy compared to placebo, 
but superiority of PCI or CABG compared to thrombolytic therapy18,27,28. 
Therefore, thrombolytic therapy is recommended only if PCI is not possible or if it 
is delayed (>90 min) and presenting early after symptom onset (<3 hours), 
followed by emergent transfer to a PCI facility20.  
The prognosis of patients with cardiogenic shock is related to the procedural 
success of PCI and importantly, patients with cardiogenic shock are less likely to 
have successful PCI than patients without shock16. Since the recruitment of the 
SHOCK trial (where only 37% of patients undergoing PCI received stents) there 
have been many advances in PCI; first bare-metal stents and more recently drug-
eluting stents have been associated with associated with a greater likelihood of 
complete revascularization, a higher incidence of TIMI 3 flow and improved 
survival in cardiogenic shock29-31.  
In the current European guidelines, infarct related cardiogenic shock is an 
indication for emergency revascularization with either PCI or CABG, if the patient 
has suitable coronary anatomy26. To date, there exist no randomized clinical 
trials that have compared PCI and CABG in patients with cardiogenic shock. In 
the SHOCK trial, the protocol recommended CABG in patients with a left main 
coronary stenosis of ≥ 50%, ≥2 total or subtotal occlusions, stenosis of >90% in 
two non-infarct-related major arteries, or stenosis unsuitable for PCI, as well as in 
patients whose PCI was unsuccessful17. However, this decision was made on an 
individual basis by site investigators and PCI was often performed in patients with 
three vessel disease. Among the 128 cardiogenic shock patients receiving 
emergency revascularization (63% PCI and 37% CABG) there was a similar 
mortality at 30 days, one year and six years regardless of method of 
revascularization14,17,18. However, in current practice, very few patients with 
cardiogenic shock and three-vessel disease are referred for CABG, ranging from 
3.2% to 8.8%32, possibly reflecting the real-world difficulties of arranging 
emergency CABG for patients with cardiogenic shock who often present 
overnight and at weekends.  
In summary, in patients with cardiogenic shock complicating acute myocardial 
infarction PCI allows prompt restoration of coronary flow which may arrest the 
vicious cycle of myocardial ischaemia and reduced cardiac output. If there is 
likely to be a significant delay to PCI, thrombolytic therapy should be considered. 
Finally, urgent CABG should also be considered in the case of unsuccessful PCI, 
left main disease, three-vessel disease, or in the presence of severe valvular 
disease and mechanical complications of myocardial infarction20,26.  
 
- Revascularisation of multi-vessel coronary artery disease?  
The majority (70-80%) of patients with cardiogenic shock complicating acute 
myocardial infarction have multi-vessel disease, which in itself is associated with 
a higher mortality compared to single vessel disease4,33-35. As discussed above, 
the current evidence does not clearly identify an optimal revascularisation 
strategy for cardiogenic shock patients with multi-vessel disease. There are four 
observational reports comparing PCI vs. CABG which suggest similar mortality 
rates36; however in current practice, CABG is rarely performed in patients with 
cardiogenic shock2,33.  
Due to the lack of reliable prospective clinical data, guideline recommendations 
have been based on physiological principles to arrest the downward spiral of 
myocardial ischaemia and reduced cardiac output. In contrast to the 
recommendations for haemodynamically stable patients, current guidelines 
recommend PCI to the culprit lesion followed by PCI to critical lesions (>90% 
stenosis) or those with unstable appearances (possible thrombus or lesion 
disruption) if there is ongoing ischaemia or haemodynamic instability20,26. The 
ongoing prospective, multi-centre CULPRIT-SHOCK trial will company culprit-
vessel treatment with complete revascularisation in cardiogenic shock.  
 
- Revascularisation of left main stem disease?  
There are no current guidelines on revascularisation for patients with left main 
coronary artery (LMCA) related myocardial infarction complicated with 
cardiogenic shock. In recent years, together with the increased use of PCI for 
LMCA in the stable setting, PCI has become the preferred method of 
revascularisation for patients with LMCA-related acute coronary syndromes37. 
The combined SHOCK trial and registry only include 21 patients with LMCA-
related myocardial infarction and there is significant treatment bias in favour of 
PCI (as many severely unstable patients will be unsuitable for surgical 
revascularisation), as such it is not possible to draw any valid conclusion from 
their outcomes14,38.  
Given the paucity of evidence, the decision to perform CABG or PCI in patients 
with cardiogenic shock and LMCA disease should be taken on an individual basis 
taking into account the clinical stability of the patient, coronary anatomy, operator 
experience and potential risks of either strategy20,26.  
  
(b) Pharmacological Management 
There have been recent summaries on the use of inotropes and vasopressor 
agents in cardiogenic shock39,40, and a review of this is beyond the scope of this 
article. In brief, regardless of the decision to revascularise, pharmacological 
stabilisation of the patient in cardiogenic shock is a complex process which 
requires judicious use of fluids to obtain euvolaemia, vasopressors and inotropes 
with the aim of preventing multi-organ hypoperfusion and ultimately failure. 
Despite their almost ubiquitous use and clear effect on haemodynamics, there 
are no randomised data showing a prognostic benefit with the use of inotropes or 
vasopressors in the setting of cardiogenic shock. Furthermore, as 
catecholeamines increase myocardial oxygen consumption and vasoconstrictors 
may impair the microcirculation as well as tissue perfusion, their use should be 




(c) Mechanical Circulatory Support 
Mechanical circulatory support should be instituted in patients with cardiogenic 
shock who remain haemodynamically unstable despite revascularisation and 
inotrope therapy41,42. In general, mechanical circulatory support devices can 
potentially be of benefit in cardiogenic shock by maintaining organ perfusion 
whist reducing myocardial oxygen demand and augmenting coronary blood flow. 
Historically, the intra-aortic balloon pump has been the only mechanical 
circulatory support device available to interventionalists during high risk PCI such 
as with a patient in cardiogenic shock33. More recently, a number of new devices 
have recently become available which include axial flow pumps (e.g. Impella), left 
atrial to femoral artery bypass pumps (e.g. TandemHeart); and new devices for 
the implementation of extracorporeal membrane oxygenation (ECMO) (Figure 2).  
 
- Intra-Aortic Balloon Pump (IABP) 
The IABP remains the most commonly used form of circulatory support in 
cardiogenic shock. The IABP has two major components, a balloon catheter 
(filled with helium) and a pump console to control the balloon (Figure 2a). It is 
commonly inserted via the femoral artery, and the balloon inflates with the onset 
of diastole (around the middle of the T-wave) and deflates at the onset of left 
ventricular systole (at the peak of the R-wave)41. This mechanism provides 
haemodynamic support by increasing diastolic perfusion pressure in the coronary 
arteries and reducing left ventricular afterload, thereby reducing wall tension and 
myocardial oxygen demand resulting in a modest elevation in cardiac output (0.3-
0.5 l/min).  
The first randomised controlled trial comparing IABP therapy to conservative 
management in 45 patients with cardiogenic shock found a reduction in BNP but 
no change in clinical outcomes (IABP SHOCK)43. This was followed with a larger 
trial of 600 patients with acute myocardial infarction complicated by cardiogenic 
shock and randomised patients to either IABP or standard therapy (IABP SHOCK 
II), which did not demonstrate a significant reduction in mortality at 30 days or 12 
months (although 86.6% of IABPs were inserted post-PCI)44. Current ESC 
guidelines advise against the routine use of IABP during PCI in patients with 
cardiogenic shock, and limit their recommendations of its use to patients with 
cardiogenic shock due mechanical complications of myocardial infarction 
awaiting surgery20,26.  
 
- Left atrial to aorta assist devices (i.e. TandemHeart) 
The Tandem Heart is a percutaneously inserted circulatory assist device that 
pumps blood extracorporeally from the left atrium to the iliofemoral arterial 
system via a transeptally placed atrial cannula, bypassing the left ventricle 
(Figure 2b)41. By working in parallel with the left ventricle, this results in a 
reduction of LV preload, filling pressures, wall stress and myocardial oxygen 
demand whilst increasing arterial blood pressure and systemic perfusion 
(increasing cardiac output up to 4 l/min).  
A retrospective analysis of patients with refractory cardiogenic shock 
demonstrated that the TandemHeart improved haemodynamics45. This was 
following by two small randomised controlled trials which demonstrated that the 
TandemHeart improved haemodynamics to a greater extent than IABP, but at a 
cost of increased complications such as severe bleeding, limb ischaemia and 
arrhythmias46,47.  
 
- Left Ventricle to Aorta Assist Device (i.e. Impella) 
The Impella is a non-pulsatile axial flow Archimedes-screw pump designed to 
propel blood from the LV into the ascending aorta in series with the LV(Figure 
2c)41. This results in direct unloading of the LV, an increase in forward flow 
associated with reduction in myocardial oxygen consumption, improvement in 
mean arterial pressure and reduction in pulmonary capillary wedge pressure. A 
number of different version are available: the percutaneous 12-F (Impella 2.5) 
device and 21-F (Impella 5.0) surgical cut down device, which provide maximal 
flow rates of 2.5 and 5.0 l/min respectively. More recently, a percutaneous 14-F 
(Impella CP) device provides an intermediate level of support similar to the 
TandemHeart (up to 4 l/min). Complications of Impella support include bleeding 
at the vascular access site, haemolysis and pericardial tamponade, whereas use 
is contraindicated in patients with severe peripheral vascular disease, presence 
of a mechanical aortic valve or a severely calcified aortic valve. 
There have been a number of studies demonstrating the safety and 
haemodynamic benefits of Impella insertion in cardiogenic shock. Recently, in the 
Efficacy Study of LV Assist Device to Treat Patients with Cardiogenic Shock 
(ISAR-SHOCK) trial, the Impella 2.5 was associated with a larger increase in 
cardiac output and mean arterial pressure compared with IABP, however, the 
there was no difference in mortality between the two groups48. 
 
- Extracorporeal membrane oxygenation (ECMO) 
The most comprehensive percutaneously inserted mechanical support is 
provided by ECMO, which can either provide oxygenation only (veno-veno [V-V] 
ECMO) or oxygenation with circulatory support (veno-arterial [V-A] ECMO). In 
cases of biventricular failure, V-A ECMO is the MCS of choice and is able to 
provide 7 l/min of non-pulsatile flow41. Similar to cardiopulmonary bypass circuits, 
V-A ECMO involves a circuit composed of a centrifugal pump, a heat exchanger 
and a membrane oxygenator. A venous cannula (20-F) drains blood from the 
right atrium into a membrane oxygenator for gas exchange, and then oxygenated 
blood is pumped into the patient via an arterial cannula (17-F) (Figure 2d).  
The main limitation of ECMO is that the retrograde flow of the peripheral arterial 
cannulation increases afterload, increasing myocardial oxygen demand and can 
precipitate pulmonary oedema. Conversely, increasing ECMO flow rates in this 
situation will worsen the haemodynamic situation. A number of techniques can be 
used to improve LV emptying including concurrent Impella usage, or venting with 
a pigtail catheter in the LV, or creation of an atrial septal defect. Failing 
resolution, central ECMO can be used with direct cannulation of the LV, LA or 
pulmonary artery.  
There are non-randomised data using historic controls suggesting that ECMO 
use for patients with myocardial infarction related cardiogenic shock can improve 
survival49-51. Although promising, using historic controls rather than a prospective 
randomised study does not account for other potential temporal advances in 
management.  
Although ECMO may improve survival of patients in cardiogenic shock, there is 
significant procedural morbidity: common complications include limb ischaemia, 
renal failure, bleeding and infection41.  
 
Conclusion  
Early revascularisation remains the cornerstone of management of patients with 
cardiogenic shock, although the optimal method remains unclear – patients who 
have the earliest revascularisation have the best outcomes. In addition to 
restoring myocardial perfusion, management of patients with cardiogenic shock 
requires haemodynamic stabilisation – predominantly through careful use of 
vasopressors and inotropes which may increase myocardial oxygen demand and 
thereby worsening ischaemia. In more recent years, a number of mechanical 
circulatory support devices have emerged that provide promising adjuvant 
therapies for patients in cardiogenic shock. These will allow for angioplasty to be 
performed in an improved haemodynamic setting and provide a bridge to 








- systolic blood pressure <90 mmHg for >30 min, or 
- vasopressors required to achieve a blood pressure ≥90 mmHg 
Elevated Left Ventricular Filling Pressures: 
- Pulmonary Congestion, or 
- Adequate or elevated filling pressures (wedge pressure >20 mmHg) 
Signs of impaired organ perfusion: (at least one of the following) 
- Altered mental status 
- Cold, clammy skin 
- Oliguria 
- Increased serum-lactate 
 
Figure 1: Kaplan-Meier Long-term Survival of All Patients in the The Should 
We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock 
(SHOCK) trial modified from Hochman et al.14  
Among all patients, the survival rates in the early revascularization (ERV) and 
initial medical stabilization (IMS) groups, respectively, were 41.4% vs 28.3% at 3 





Figure 2: Peripheral ventricular assist devices, modified from Thiele et al.52  
Schematic diagram to demonstrate the access site and mechanism of action of: 
a) Intra-aortic balloon pump (IABP)  
b) Impella 
c) TandemHeart 
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